首页> 外文期刊>American journal of clinical pathology. >Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
【24h】

Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.

机译:比较流式细胞技术评估ZAP-70在慢性淋巴细胞白血病中与IgVH突变状态有关的表达。

获取原文
获取原文并翻译 | 示例
           

摘要

We compared 1 subjective and 5 objective flow cytometric methods to evaluate zeta-associated protein (ZAP-70) expression in relation to immunoglobulin heavy-chain variable-region (IgVH) gene mutational status in 154 samples from 125 patients with chronic lymphocytic leukemia (CLL). ZAP-70 expression determined by all methods used correlated with IgVH gene mutational status, but none of them demonstrated high concordance rates. Of the objective methods, ZAP-70 staining determined as a ratio of molecules of equivalent soluble fluorochrome intensity in CLL cells to that in normal B cells (ZAP-70+ staining in IgVH germline cases, 59%; ZAP-70- in IgVH mutated cases, 75%) or T cells (ZAP-70+ in IgVH germline cases, 66%; ZAP-70- in IgVH mutated cases, 57%) provides the best combination for assigning ZAP-70+ status to IgVH germline and ZAP-70- status to IgVH mutated cases. The subjective method based on ZAP-70 expression in natural killer/T cells gave a similar result, but reproducibility between laboratories may be difficult. Further studies on ZAP-70 expression in relation to clinical parameters may address whether ZAP-70 is an independent prognostic marker for CLL.
机译:我们比较了125种慢性淋巴细胞性白血病(CLL)患者的154个样本中的1种主观和5种客观流式细胞术方法,以评估与免疫球蛋白重链可变区(IgVH)基因突变状态相关的zeta相关蛋白(ZAP-70)表达)。通过所有使用的方法确定的ZAP-70表达与IgVH基因突变状态相关,但没有一个显示出高一致性。在客观方法中,ZAP-70染色确定为CLL细胞与正常B细胞​​中等效可溶性荧光强度分子的比率(IgVH种系病例中ZAP-70 +染色为59%; IgVH中的ZAP-70-突变病例(75%)或T细胞(在IgVH种系病例中为ZAP-70 +,占66%;在IgVH突变病例中为ZAP-70-,占57%)为将IAPV70 +状态分配给IgVH种系和ZAP- IgVH突变病例为70-。基于自然杀手/ T细胞中ZAP-70表达的主观方法得出了类似的结果,但是实验室之间的可重复性可能很困难。有关临床参数的ZAP-70表达的进一步研究可能会解决ZAP-70是否是CLL的独立预后标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号